The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Since celebrities first started talking about Ozempic, demand for the GLP-1 drugs have soared, leaving major manufacturers Novo Nordisk and Eli Lilly scrambling to address pressing drug shortages. The ...

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

StudyFinds' Dr. Faith Coleman looks at the common mistakes patients make using GLP-1 agonists like Ozempic and Wegovy.

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...